octreotide

Summary

Summary: A potent, long-acting synthetic SOMATOSTATIN octapeptide analog that inhibits secretion of GROWTH HORMONE and is used to treat hormone-secreting tumors; DIABETES MELLITUS; HYPOTENSION, ORTHOSTATIC; HYPERINSULINISM; hypergastrinemia; and small bowel fistula.

Top Publications

  1. ncbi Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group
    Anja Rinke
    Department of Internal Medicine, Division of Gastroenterology and Endocrinology, Institute of Medical Biometry and Epidemiology, Philipps University, Marburg, Germany
    J Clin Oncol 27:4656-63. 2009
  2. ncbi Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
    Marianne E Pavel
    Charite Universitatsmedizin Berlin Campus Virchow Klinikum, Berlin, Germany
    Lancet 378:2005-12. 2011
  3. ncbi Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival
    Dik J Kwekkeboom
    Department of Nuclear Medicine, Erasmus Medical Center, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
    J Clin Oncol 26:2124-30. 2008
  4. pmc Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study
    James C Yao
    Department of Gastrointestinal Medical Oncology, Unit 426, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 26:4311-8. 2008
  5. pmc Meta-analysis on the effects of octreotide on tumor mass in acromegaly
    Andrea Giustina
    Department of Medical and Surgical Sciences, University of Brescia, Montichiari Hospital, Brescia, Italy
    PLoS ONE 7:e36411. 2012
  6. ncbi Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancers
    Linda Villard
    University Hospital Basel, Petersgraben 4, CH 4031 Basel, Switzerland
    J Clin Oncol 30:1100-6. 2012
  7. ncbi Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers
    Anna Imhof
    Institute of Nuclear Medicine, University Hospital, Petersgraben 4, Basel, Switzerland
    J Clin Oncol 29:2416-23. 2011
  8. ncbi Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate
    Roelf Valkema
    Department of Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
    J Nucl Med 46:83S-91S. 2005
  9. ncbi Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors
    Dik J Kwekkeboom
    Department of Nuclear Medicine, Erasmus Medical Center, s Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands
    Endocr Relat Cancer 17:R53-73. 2010
  10. ncbi The eradication of breast cancer and cancer stem cells using octreotide modified paclitaxel active targeting micelles and salinomycin passive targeting micelles
    Yang Zhang
    State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China
    Biomaterials 33:679-91. 2012

Detail Information

Publications346 found, 100 shown here

  1. ncbi Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group
    Anja Rinke
    Department of Internal Medicine, Division of Gastroenterology and Endocrinology, Institute of Medical Biometry and Epidemiology, Philipps University, Marburg, Germany
    J Clin Oncol 27:4656-63. 2009
    ..We performed a placebo-controlled, double-blind, phase IIIB study in patients with well-differentiated metastatic midgut NETs. The hypothesis was that octreotide LAR prolongs time to tumor progression and survival.
  2. ncbi Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
    Marianne E Pavel
    Charite Universitatsmedizin Berlin Campus Virchow Klinikum, Berlin, Germany
    Lancet 378:2005-12. 2011
    ..We aimed to assess the combination of everolimus plus octreotide long-acting repeatable (LAR) in patients with low-grade or intermediate-grade neuroendocrine tumours (carcinoid).
  3. ncbi Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival
    Dik J Kwekkeboom
    Department of Nuclear Medicine, Erasmus Medical Center, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
    J Clin Oncol 26:2124-30. 2008
    ..Here we report on the toxicity and efficacy of this treatment, performed in over 500 patients...
  4. pmc Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study
    James C Yao
    Department of Gastrointestinal Medical Oncology, Unit 426, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 26:4311-8. 2008
    Evaluate the activity of everolimus (RAD001) in combination with octreotide long-acting repeatable (LAR) in patients with advanced low- to intermediate-grade neuroendocrine tumors.
  5. pmc Meta-analysis on the effects of octreotide on tumor mass in acromegaly
    Andrea Giustina
    Department of Medical and Surgical Sciences, University of Brescia, Montichiari Hospital, Brescia, Italy
    PLoS ONE 7:e36411. 2012
    The long-acting somatostatin analogue octreotide is used either as an adjuvant or primary therapy to lower growth hormone (GH) levels in patients with acromegaly and may also induce pituitary tumor shrinkage.
  6. ncbi Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancers
    Linda Villard
    University Hospital Basel, Petersgraben 4, CH 4031 Basel, Switzerland
    J Clin Oncol 30:1100-6. 2012
    ..Radiopeptide therapy is commonly performed with a single radioisotope. We aimed to compare the effectiveness of somatostatin-based radiopeptide therapy with a single versus a combination of radioisotopes...
  7. ncbi Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers
    Anna Imhof
    Institute of Nuclear Medicine, University Hospital, Petersgraben 4, Basel, Switzerland
    J Clin Oncol 29:2416-23. 2011
    To investigate response, survival, and safety profile of the somatostatin-based radiopeptide (90)yttrium-labeled tetraazacyclododecane-tetraacetic acid modified Tyr-octreotide ([(90)Y-DOTA]-TOC) in neuroendocrine cancers.
  8. ncbi Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate
    Roelf Valkema
    Department of Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
    J Nucl Med 46:83S-91S. 2005
    ..during a follow-up of at least 18 mo after the start of PRRT with (90)Y-1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA),Tyr(3)-octreotide ((90)Y-DOTATOC) or (177)Lu-DOTA(0),Tyr(3)-octreotate ((177)Lu-DOTATATE).
  9. ncbi Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors
    Dik J Kwekkeboom
    Department of Nuclear Medicine, Erasmus Medical Center, s Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands
    Endocr Relat Cancer 17:R53-73. 2010
    Somatostatin receptor imaging (SRI) with [(111)In-DTPA(0)]octreotide has proven its role in the diagnosis and staging of gastroenteropancreatic neuroendocrine tumors (GEPNETs)...
  10. ncbi The eradication of breast cancer and cancer stem cells using octreotide modified paclitaxel active targeting micelles and salinomycin passive targeting micelles
    Yang Zhang
    State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China
    Biomaterials 33:679-91. 2012
    ..breast cancer cells and breast cancer stem cells which can not be eliminated by the conventional chemotherapy, octreotide (Oct)-modified paclitaxel (PTX)-loaded PEG-b-PCL polymeric micelles (Oct-M-PTX) and salinomycin (SAL)-loaded PEG-..
  11. ncbi Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors
    Amy Moreno
    Department of Surgical Oncology, Division of Quantitative Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Endocr Relat Cancer 15:257-66. 2008
    ..b>Octreotide, a somatostatin analog, decreases phosphatidylinositol-3-kinase/Akt signaling in some models, and thus ..
  12. ncbi Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b
    James C Yao
    Department of Gastrointestinal Medical Oncology, Unit 426, The University of Texas M D Anderson Cancer, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 26:1316-23. 2008
    ..Effective systemic therapy for advanced carcinoid is lacking. The combination of bevacizumab (BEV) and pegylated (PEG) interferon alpha-2b was evaluated among patients with metastatic or unresectable carcinoid tumors...
  13. ncbi Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors
    Roelf Valkema
    Department of Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
    Semin Nucl Med 36:147-56. 2006
    ..study with cumulative doses of 47 mCi to 886 mCi of the radiolabeled somatostatin analog [(90)Y-DOTA(0),Tyr(3)]-octreotide. At baseline, 47 patients had progressive disease, and 36 were symptomatic...
  14. ncbi 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT
    Michael Gabriel
    Department of Nuclear Medicine, Innsbruck Medical University, Innsbruck, Austria
    J Nucl Med 48:508-18. 2007
    ..analog, (68)Ga-labeled 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid-d-Phe(1)-Tyr(3)-octreotide ((68)Ga-DOTA-TOC), for PET in patients with known or suspected neuroendocrine tumors...
  15. ncbi The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors
    Andrea Frilling
    Department of General, Visceral and Transplantation Surgery, University Hospital Essen, Essen, Germany
    Ann Surg 252:850-6. 2010
    ..To evaluate the impact of 68Ga-DOTATOC positron emission tomography (PET)/computed tomography (CT) on the multimodal management of neuroendocrine tumors (NET)...
  16. ncbi Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy
    Daniel Putzer
    Department of Nuclear Medicine, Innsbruck Medical University, Innsbruck, Austria
    J Nucl Med 50:1214-21. 2009
    ..We compared the diagnostic value of CT with that of the novel somatostatin analog (68)Ga-1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid-d-Phe(1)-Tyr(3)-octreotide ((68)Ga-DOTATOC) in the detection of such metastases.
  17. ncbi Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro
    Sarah Lesche
    Department of Pharmacology and Toxicology, Otto von Guericke University, Magdeburg, Germany
    J Clin Endocrinol Metab 94:654-61. 2009
    The clinically used somatostatin analogs, octreotide and lanreotide, act primarily by binding to somatostatin receptor 2 (sst2)...
  18. ncbi ¹¹¹In-DTPA⁰-octreotide (Octreoscan), ¹³¹I-MIBG and other agents for radionuclide therapy of NETs
    Jamshed B Bomanji
    Institute of Nuclear Medicine, University College Hospital, 235 Euston Road, London NW1 2BU, UK
    Eur J Nucl Med Mol Imaging 39:S113-25. 2012
    This paper is a critical review of the literature on NET radionuclide therapy with (111)In-DTPA(0)-octreotide (Octreoscan) and (131)I-MIBG, focusing on efficacy and toxicity...
  19. ncbi Differential antiinflammatory and antinociceptive effects of the somatostatin analogs octreotide and pasireotide in a mouse model of immune-mediated arthritis
    Anne Katja Imhof
    University Hospital and Friedrich Schiller University Jena, Jena, Germany
    Arthritis Rheum 63:2352-62. 2011
    ..The purpose of this study was to assess the effects of the stable somatostatin analogs octreotide and pasireotide (SOM230) in a mouse model of antigen-induced arthritis (AIA).
  20. ncbi DG3173 (somatoprim), a unique somatostatin receptor subtypes 2-, 4- and 5-selective analogue, effectively reduces GH secretion in human GH-secreting pituitary adenomas even in Octreotide non-responsive tumours
    U Plockinger
    Interdisziplinäres Stoffwechsel Centrum, Charite Universitatsmedizin Berlin, Campus Virchow Klinikum, Augustenburger Platz 1, 13353 Berlin, Germany
    Eur J Endocrinol 166:223-34. 2012
    ..We investigated the effect of DG3173, including its relation to specific tumour characteristics, on GH secretion in human somatotroph adenoma cell cultures (hSA) in comparison with Octreotide.
  21. ncbi 90Y-edotreotide for metastatic carcinoid refractory to octreotide
    David L Bushnell
    Department of Radiology, University of Iowa Roy J and Lucille A Carver College of Medicine, 200 Hawkins Dr, Iowa City, IA 52242, USA
    J Clin Oncol 28:1652-9. 2010
    ..Although symptom relief is available with octreotide, the disease eventually becomes refractory to octreotide, leaving no proven treatment options...
  22. pmc [68Ga]-DOTATOC-PET/CT for meningioma IMRT treatment planning
    Barbara Gehler
    Department of Radiation Oncology, LMU Munchen, Marchioninistr, 15, 81377 Munchen, Germany
    Radiat Oncol 4:56. 2009
    ....
  23. ncbi Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours
    Andreas Helisch
    Department of Nuclear Medicine, University of Mainz, Mainz, Germany
    Eur J Nucl Med Mol Imaging 31:1386-92. 2004
    ..tumours, the somatostatin analogue DOTATOC labelled with 90Y is frequently used [90Y-DOTA-Phe1-Tyr3)-octreotide (SMT487-OctreoTher)]...
  24. ncbi Hepatic artery chemoinfusion with chemoembolization for neuroendocrine cancer with progressive hepatic metastases despite octreotide therapy
    Dara Christante
    Department of Surgery, Division of Surgical Oncology, Oregon Health and Science University, Portland, Ore, USA
    Surgery 144:885-93; discussion 893-4. 2008
    ..Several treatment modalities have been examined, but an optimal treatment approach has been difficult to define. We evaluated a regimen combining hepatic artery chemoinfusion with chemoembolization...
  25. ncbi Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC
    Christian Waldherr
    PET Center, Institute of Nuclear Medicine, University Hospital, University of Basel, Basel, Switzerland
    J Nucl Med 43:610-6. 2002
    ..somatostatin analog (90)Y-1,4,7,10-tetra-azacyclododecan-4,7,10-tricarboxy-methyl-1-yl-acetyl-D-Phe-Tyr(3)-octreotide (DOTATOC)...
  26. ncbi Octreotide may act as a radioprotective agent in acromegaly
    A M Landolt
    Neurosurgery Section, Klinik Im Park, Zurich, Switzerland
    J Clin Endocrinol Metab 85:1287-9. 2000
    ..undergoing radiation treatment for recurring acromegaly or acromegaly persisting after surgery are treated with octreotide. We, therefore, performed a follow-up study of patients undergoing stereotactic radiosurgery (Gamma Knife) to ..
  27. ncbi Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial
    S Petersenn
    Division of Endocrinology, Medical Center, University of Duisburg Essen, Hufelandstrasse 55, 45122 Essen, Germany
    J Clin Endocrinol Metab 95:2781-9. 2010
    ..Because most GH-secreting pituitary adenomas express sst(2) and sst(5), pasireotide has the potential to be more effective than the sst(2)-preferential somatostatin analogs octreotide and lanreotide.
  28. ncbi Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors
    Dik J Kwekkeboom
    Department of Nuclear Medicine, Erasmus Medical Center, Dr Molewaterplein 40, 3015 GD Rotterdam, Netherlands
    J Clin Oncol 23:2754-62. 2005
    ..Chemotherapy can be effective, but the response is usually less than 1 year. Here, we present the results of treatment with a radiolabeled somatostatin analog, [177Lu-DOTA0,Tyr3]octreotate (177Lu-octreotate)...
  29. ncbi Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine
    Edgar J Rolleman
    Department of Nuclear Medicine, Erasmus Medical Centre, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
    Eur J Nucl Med Mol Imaging 30:9-15. 2003
    As scintigraphy with [(111)In-DTPA(0)]octreotide has become a standard technique in analysing somatostatin receptor-receptor positive lesions such as neuroendocrine tumours, a logical next step is peptide receptor radionuclide therapy (..
  30. ncbi Octreotide therapy of pediatric hypothalamic obesity: a double-blind, placebo-controlled trial
    Robert H Lustig
    Department of Endocrinology, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    J Clin Endocrinol Metab 88:2586-92. 2003
    ..We report the results of a randomized, double-blind, placebo-controlled trial of octreotide therapy for pediatric hypothalamic obesity. Eighteen subjects [weight, 100.6 +/- 5...
  31. ncbi Long-acting somatostatin analog therapy of acromegaly: a meta-analysis
    Pamela U Freda
    Department of Medicine, Columbia University, College of Physicians and Surgeons, 630 West 168th Street, New York, New York 10032, USA
    J Clin Endocrinol Metab 90:4465-73. 2005
    ..Although considerable data exist on the use of long-acting somatostatin analogs to treat acromegaly, their reported efficacy differs substantially among trials...
  32. ncbi Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study
    Larry K Kvols
    H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    Endocr Relat Cancer 19:657-66. 2012
    ..symptom control in patients with neuroendocrine tumors (NETs) and carcinoid syndrome no longer responsive to octreotide LAR...
  33. ncbi Somatostatin receptor sst2 decreases cell viability and hormonal hypersecretion and reverses octreotide resistance of human pituitary adenomas
    Julie Acunzo
    Center of Research in Neurobiology Neurophysiology of Marseille, UMR 6231 Centre National de la Recherche Scientifique, Institut Federatif Jean Roche, University of Mediterranee, Marseille, France
    Cancer Res 68:10163-70. 2008
    ..somatotroph adenomas, growth hormone (GH) hypersecretion can be inhibited by somatostatin analogues such as octreotide. Unfortunately, serum GH levels reach normal values in only 60% of treated patients...
  34. ncbi Somatostatin receptor-mediated tumor-targeting drug delivery using octreotide-PEG-deoxycholic acid conjugate-modified N-deoxycholic acid-O, N-hydroxyethylation chitosan micelles
    Meirong Huo
    State Key Laboratory of Natural Medicines, Department of Pharmaceutics, China Pharmaceutical University, Nanjing 210009, China
    Biomaterials 33:6393-407. 2012
    In this study, a ligand-PEG-lipid conjugate, octreotide-polyethene glycol-deoxycholic acid (OCT(Phe)-PEG-DOCA, or OPD) was successfully synthesized and used as a targeting molecule for N-deoxycholic acid-O, N-hydroxyethylation chitosan (..
  35. ncbi Successful treatment of congenital hyperinsulinism with long-acting release octreotide
    Kim Hanh Le Quan Sang
    Centre de Référence des Maladies Héréditaires du Métabolisme, Hopital Necker Enfants Malades, AP HP, Universite Paris Descartes, 149 rue de Sevres, 75015 Paris, France
    Eur J Endocrinol 166:333-9. 2012
    ..Congenital hyperinsulinism (HI) is a common cause of hypoglycemia in infancy. The medical treatment of diazoxide-unresponsive HI is based on a somatostatin analogue...
  36. pmc Evaluation of the role of [18F]FDG-PET/CT and [68Ga]DOTATOC-PET/CT in differentiating typical and atypical pulmonary carcinoids
    Tarun Jindal
    Department of General Surgery, All India Institute of Medical Sciences, New Delhi, India
    Cancer Imaging 11:70-5. 2011
    ..PET)/computed tomography (CT) and [68Ga]1,4,7,10-tetraazacyclododecane-N(I-IIII)-tetraacetic acid-(D)-Phe1-Thy3-octreotide (DOTATOC)-PET/CT...
  37. ncbi Octreotide-targeted liposomes loaded with CPT-11 enhanced cytotoxicity for the treatment of medullary thyroid carcinoma
    Yuko Iwase
    Institute of Medicinal Chemistry, Hoshi University, Ebara 2 4 41, Shinagawa, Tokyo 142 8501, Japan
    Mol Pharm 8:330-7. 2011
    ..MTC is known to overexpress the somatostatin receptor subtype 2 (SSTR2). Octreotide (Oct) is a somatostatin analogue that has a high binding affinity for SSTR and can be used as a tumor-targeting ..
  38. ncbi Fluorodeoxyglucose positron emission tomography and somatostatin receptor scintigraphy for diagnosing and staging carcinoid tumours: correlations with the pathological indexes p53 and Ki-67
    T Belhocine
    Division of Nuclear Medicine, Centre Hospitalier Universitaire, Sart Tilman, B35 4000 Liège 1, Belgium
    Nucl Med Commun 23:727-34. 2002
    ..We conclude that SRS remains the modality of choice for evaluating patients with carcinoid tumours, regardless of their proliferative activity. FDG PET should be reserved to patients with negative results on SRS...
  39. ncbi Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE
    Irene Virgolini
    Medical University of Innsbruck, Innsbruck, Austria
    Eur J Nucl Med Mol Imaging 37:2004-10. 2010
    ..the results of somatostatin (SST) receptor PET/CT imaging using 68Ga-DOTA-conjugated peptides, analogues of octreotide, that bind to SST receptors...
  40. ncbi Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study
    Tullio Florio
    Department of Oncology, Biology and Genetics, University of Genova, Viale Benedetto XV, 2, 16132 Genova, Italy
    Endocr Relat Cancer 15:583-96. 2008
    ..inhibition obtained in 17 out of 27 tumors using BIM-23A760, in the same subgroup of adenomas analyzed), while octreotide was effective in 13 out of 27 cases...
  41. ncbi Expression of type 5 somatostatin receptor in TSH-secreting pituitary adenomas: a possible marker for predicting long-term response to octreotide therapy
    Ai Yoshihara
    Department of Medicine, Institute of Clinical Endocrinology, Tokyo Women s Medical University, Japan
    Endocr J 54:133-8. 2007
    In TSH-secreting pituitary adenomas (TSHoma), octreotide (OCT) therapy reduces tumor size and TSH secretion in some cases but not in others...
  42. ncbi Discontinuation of octreotide LAR after long term, successful treatment of patients with acromegaly: is it worth trying?
    Claudia Ramirez
    Endocrinology Service and Experimental Endocrinology Unit, Hospital de Especialidades, CMN S XXI, IMSS, Aristòteles 68, Polanco 11560, Mexico City, Mexico
    Eur J Endocrinol 166:21-6. 2012
    ..Somatostatin analogs (SA) have been used for over 25 years in the treatment of acromegaly. A major disadvantage is the need to continue therapy indefinitely...
  43. ncbi Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68Ga-DOTATOC PET/CT
    Matthias Miederer
    Department of Nuclear Medicine, Klinikum rechts der Isar, Technische Universitat Munchen, Ismaningerstrasse 22, 81675, Munchen, Germany
    Eur J Nucl Med Mol Imaging 36:48-52. 2009
    ..routine somatostatin analogue positron emission tomography/computed tomography (PET/CT) such as (68)Ga-DOTA-Tyr-octreotide (DOTATOC)-PET/CT could substitute conventional (111)In-Octreotide scintigraphy...
  44. ncbi The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study
    C Waldherr
    Department of Nuclear Medicine with PET Center, University Hospital, Basel, Switzerland
    Ann Oncol 12:941-5. 2001
    ..In addition, the palliative effect of 90Y-DOTATOC treatment on the malignant carcinoid syndrome and tumour-associated pain was investigated...
  45. ncbi Short-term preoperative octreotide treatment of GH-secreting pituitary adenoma: predictors of tumor shrinkage
    Satoru Oshino
    Department of Neurosurgery, Osaka University Graduate School of Medicine, Japan
    Endocr J 53:125-32. 2006
    We reviewed the cases of 32 patients with growth hormone (GH)-secreting macroadenoma who underwent short-term octreotide treatment before transsphenoidal surgery to determine which types of adenoma the preoperative treatment were ..
  46. pmc Successful treatment of protein-losing enteropathy induced by intestinal lymphangiectasia in a liver cirrhosis patient with octreotide: a case report
    Hang Lak Lee
    Department of Internal Medicine, Hanyang University Kuri Hospital, Guri, Korea
    J Korean Med Sci 19:466-9. 2004
    ..During hospitalization, he received subcutaneous octreotide therapy...
  47. ncbi Somatostatin receptor subtypes mediate contractility on human colonic smooth muscle cells
    V D Corleto
    Department of Digestive and Liver Diseases, 1st and 2nd Schools of Medicine, University La Sapienza, Rome, Italy
    Neurogastroenterol Motil 18:217-25. 2006
    ..CH-288, a sstr subtype 1-specific analogue, and octreotide, a sstr subtype 2-specific analogue, were the most effective relaxant analogues on longitudinal and circular SMC,..
  48. ncbi Experience with indium-111 and yttrium-90-labeled somatostatin analogs
    I Virgolini
    Department of Nuclear Medicine, University of Vienna, A 1090, Vienna, Austria
    Curr Pharm Des 8:1781-807. 2002
    ..receptors (SSTR) on various tumor cells has provided the molecular basis for successful use of radiolabeled octreotide / lanreotide analogs as tumor tracers in nuclear medicine...
  49. ncbi Treatment of neuroendocrine GEP tumours with somatostatin analogues: a review
    R Arnold
    Department of Internal Medicine, Philipps University, Marburg, Germany
    Digestion 62:84-91. 2000
    ..Somatostatin and its long-acting analogues are effective in symptom control in patients with functionally active neuroendocrine GEP tumours. Several in vitro and in vivo reports suggest that they are also able to control tumour growth...
  50. pmc Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma
    Derek R Johnson
    Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
    Neuro Oncol 13:530-5. 2011
    The objective of this phase II study was to evaluate the efficacy and safety of subcutaneous octreotide therapy for the treatment of recurrent meningioma and meningeal hemangiopericytoma...
  51. pmc Oxidative stress and ERK1/2 phosphorylation as predictors of outcome in hepatocellular carcinoma patients treated with sorafenib plus octreotide LAR
    M Caraglia
    Department of Biochemistry and Biophysics, Second University of Naples, Naples, Italy
    Cell Death Dis 2:e150. 2011
    We reported a relevant activity of the combination between sorafenib and octreotide long-acting release (LAR) in advanced hepatocellular carcinoma (HCC) patients...
  52. ncbi Peptide receptor radionuclide therapy with Y-DOTATOC and (177)Lu-DOTATOC in advanced neuroendocrine tumors: results from a Danish cohort treated in Switzerland
    Andreas Klaus Pfeifer
    Department of Clinical Physiology, Nuclear Medicine and PET, University of Copenhagen, Copenhagen, Denmark
    Neuroendocrinology 93:189-96. 2011
    ..Promising results of initial studies have warranted the implementation of peptide receptor radionuclide therapy (PRRT) in clinical practice. However, this treatment option still needs clinical evaluation...
  53. pmc Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA(0),Tyr(3)]octreotate
    Flavio Forrer
    Department of Nuclear Medicine, Erasmus MC Rotterdam, Dr Molewaterplein 40, NL 3015 GD, Rotterdam, The Netherlands
    Eur J Nucl Med Mol Imaging 36:1138-46. 2009
    ..Also, we evaluated the absorbed cross-dose from the source organs (liver, spleen, kidneys and blood), tumours and the so-called "remainder of the body" to the bone marrow...
  54. pmc Doxorubicin and octreotide induce a 40 kDa breakdown product of p53 in human hepatoma and tumoral colon cell lines
    Zahia Sadji-Ouatas
    INSERM U327, Faculte de Medecine Xavier Bichat, IFR 02, 16 rue Henri Huchard, BP 416, 75870, Paris Cedex 18, France
    Biochem J 364:881-5. 2002
    The chemotherapeutic drug doxorubicin and the anti-proliferative long-acting somatostatin analogue octreotide, both used in cancer treatment, have been shown to increase the expression of the p53 tumour suppressor protein...
  55. pmc Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease
    Marie C Hogan
    Division of Nephrology and Hypertension, Department of Biomedical STatistics and Informatics, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    J Am Soc Nephrol 21:1052-61. 2010
    ..PKD (ADPKD) or autosomal dominant PLD (ADPLD) in a randomized, double-blind, placebo-controlled trial of octreotide, a long-acting somatostatin analogue...
  56. ncbi Optimizing medical therapy of acromegaly: beneficial effects of cabergoline in patients uncontrolled with long-acting release octreotide
    Raquel S Jallad
    Neuroendocrine Unit, Division of Endocrinology and Metabolism, Hospital das Clinicas, University of Sao Paulo Medical School, Sao Paulo, Brazil
    Neuroendocrinology 90:82-92. 2009
    ..Previous data indicate a beneficial effect of cabergoline (CAB) association to somatostatin analogs (SA) in acromegalics resistant to SA monotherapy...
  57. ncbi An intrapatient comparison of 99mTc-EDDA/HYNIC-TOC with 111In-DTPA-octreotide for diagnosis of somatostatin receptor-expressing tumors
    Michael Gabriel
    Department of Nuclear Medicine, University of Innsbruck, Innsbruck, Austria Institute of Biostatistics, University of Innsbruck, Innsbruck, Austria Nuclear Medicine Research Laboratory, St Bartholomew s Hospital, London, United Kingdom
    J Nucl Med 44:708-16. 2003
    ..compare the imaging abilities of the recently developed somatostatin analog, (99m)Tc-hydrazinonicotinyl-Tyr(3)-octreotide ((99m)Tc-HYNIC-TOC [(99m)Tc-TOC]), with (111)In-diethylenediaminepentaacetic acid-D-Phe(1)-octreotide ((111)In-..
  58. ncbi Hybrid PET/MRI of intracranial masses: initial experiences and comparison to PET/CT
    Andreas Boss
    Department of Diagnostic and Interventional Radiology, Eberhard Karls University Tubingen, Tubingen, Germany
    J Nucl Med 51:1198-205. 2010
    ....
  59. ncbi Octreotide in the prevention of intra-abdominal complications following elective pancreatic resection: a prospective, multicenter randomized controlled trial
    Bertrand Suc
    Gastrointestinal Surgery Unit, Hopital Rangueil, Toulouse, France
    Arch Surg 139:288-94; discussion 295. 2004
    Prophylactic administration of octreotide acetate decreases the rate of postoperative intra-abdominal complications (IACs) after elective pancreatic resection.
  60. ncbi The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy
    Rajaventhan Srirajaskanthan
    Neuroendocrine Tumour Unit, Royal Free Hospital, London, UK
    J Nucl Med 51:875-82. 2010
    111)In-diethylenetriaminepentaacetic acid (DTPA)-octreotide scintigraphy is currently the nuclear medicine imaging modality of choice for identifying neuroendocrine tumors...
  61. pmc A multicenter, randomized, double-blind, placebo-controlled, dose-finding trial of a long-acting formulation of octreotide in promoting weight loss in obese adults with insulin hypersecretion
    R H Lustig
    Division of Pediatric Endocrinology, University of California San Francisco School of Medicine, San Francisco, CA 94143 0434, USA
    Int J Obes (Lond) 30:331-41. 2006
    To compare changes in weight in obese patients who received long-acting octreotide (octreotide LAR) at one of three dose levels (20, 40, or 60 mg) or placebo over 6 months and to identify the lowest dose of octreotide LAR that safely ..
  62. pmc A novel facile method of labeling octreotide with (18)F-fluorine
    Peter Laverman
    Department of Nuclear Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    J Nucl Med 51:454-61. 2010
    ..The method is characterized by the labeling of NOTA-octreotide (NOTA-d-Phe-cyclo[Cys-Phe-d-Trp-Lys-Thr-Cys]-Throl (MH(+) 1305) [IMP466]) with (18)F.
  63. ncbi A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly
    Robert D Murray
    Department of Endocrinology, Leeds Teaching Hospitals National Health Service Trust, Leeds, UK
    J Clin Endocrinol Metab 93:2957-68. 2008
    ..Recent analysis of the relative efficacy of octreotide LAR and lanreotide SR on the GH-IGF-I axis in acromegaly favored octreotide LAR in the secondary treatment of ..
  64. ncbi A comparison of (111)In-DOTATOC and (111)In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours
    F Forrer
    Institute of Nuclear Medicine, University Hospital, Petersgraben 4, 4031, Basel, Switzerland
    Eur J Nucl Med Mol Imaging 31:1257-62. 2004
    Yttrium-90-DOTA-Tyr(3)]-octreotide (DOTATOC) and [(177)Lu-DOTA-Tyr(3)-Thr(8)]-octreotide (DOTATATE) are used for peptide receptor-mediated radionuclide therapy (PRMRT) in neuroendocrine tumours...
  65. ncbi Pasireotide (SOM230): development, mechanism of action and potential applications
    Herbert A Schmid
    Novartis Institutes for BioMedical Research, Oncology Research, Novartis Pharma AG, Basel, Switzerland
    Mol Cell Endocrinol 286:69-74. 2008
    ..of multiple sst receptors in carcinoid tumors suggests that pasireotide may have clinical advantages over octreotide in patients with carcinoid tumors...
  66. ncbi Comparison of [(177)Lu-DOTA(0),Tyr(3)]octreotate and [(177)Lu-DOTA(0),Tyr(3)]octreotide: which peptide is preferable for PRRT?
    J P Esser
    Department of Nuclear Medicine, Erasmus MC Rotterdam, The Netherlands
    Eur J Nucl Med Mol Imaging 33:1346-51. 2006
    ..Some use octreotide as the peptide for peptide receptor radionuclide therapy (PRRT)...
  67. ncbi Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression
    Marily Theodoropoulou
    Department of Endocrinology, Max Planck Institute of Psychiatry, Kraepelinstrasse 10, D 80804 Munich, Germany
    Cancer Res 66:1576-82. 2006
    ..In this study, it is shown that in pituitary tumor cells, the somatostatin analogue octreotide produces its antiproliferative action by inducing the expression the tumor suppressor gene Zac1...
  68. ncbi PET imaging of somatostatin receptors using [68GA]DOTA-D-Phe1-Tyr3-octreotide: first results in patients with meningiomas
    M Henze
    Department of Nuclear Medicine, University of Heidelberg, Heidelberg, Germany
    J Nucl Med 42:1053-6. 2001
    Imaging of somatostatin receptors (SSTRs) using [111In]diethylenetriaminepentaacetic-acid-octreotide (DTPAOC) has proven to be helpful in the differentiation of meningiomas, neurinomas or neurofibromas, and metastases as well as in the ..
  69. pmc Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate
    D J Kwekkeboom
    Department of Nuclear Medicine, Erasmus Medical Center, Dr Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands
    Eur J Nucl Med Mol Imaging 30:417-22. 2003
    ..Treatment with the radiolabelled somatostatin analogue [(90)Y-DOTA(0),Tyr(3)]octreotide may result in partial remissions in 10-25% of patients...
  70. ncbi Medical therapy of acromegaly: efficacy and safety of somatostatin analogues
    Richard A Feelders
    Department of Internal Medicine, Section of Endocrinology, Erasmus Medical Center, Rotterdam, The Netherlands
    Drugs 69:2207-26. 2009
    ..The currently available somatostatin analogues, octreotide and lanreotide, seem to be equally effective; however, this should still be evaluated in prospective, randomized ..
  71. ncbi Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs
    Marion de Jong
    Department of Nuclear Medicine, Erasmus Medical College, Rotterdam, The Netherlands
    J Nucl Med 46:13S-7S. 2005
    ..Suitable radionuclides are (90)Y, a pure, high-energy beta-emitter (2.27 MeV), and (177)Lu, a medium-energy beta-emitter (0.5 MeV) with a low-abundance gamma...
  72. ncbi Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours
    I Buchmann
    Department of Nuclear Medicine, University Hospital Heidelberg, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany
    Eur J Nucl Med Mol Imaging 34:1617-26. 2007
    ..The aim of our study was to compare the value of (68)Ga-DOTATOC PET and (111)In-DTPAOC SPECT (Octreoscan) in the detection of NET manifestations...
  73. ncbi Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study
    Salvatore Del Prete
    Medical Oncology Unit, San Giovanni di Dio Hospital, Via Giovanni XXII, 80020, Frattaminore, Naples, Italy
    Cancer Chemother Pharmacol 66:837-44. 2010
    ..Sorafenib is a multikinase inhibitor with proven activity in advanced HCC. Octreotide is used in this setting with conflicting results...
  74. ncbi Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: a prospective, randomized trial
    Sven M Carlsen
    Department of Endocrinology, St Olavs Hospital, University Hospital of Trondheim, 7006 Trondheim, Norway
    J Clin Endocrinol Metab 93:2984-90. 2008
    ..Surgery is the primary treatment of acromegaly. However, it often fails to cure the patient. New strategies that improve surgical outcome are needed...
  75. ncbi Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review
    Gherardo Mazziotti
    Department of Medical and Surgical Sciences, University of Brescia, c o Endocrinology Service, Montichiari Hospital, Via Ciotti 154, 25018, Montichiari, Italy
    Pituitary 13:60-7. 2010
    ..However, most of the data are from patients under treatment with octreotide, either subcutaneously or intramuscularly with long-acting formulation, whereas the data on lanreotide SR or ..
  76. ncbi Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide
    P Angeli
    Department of Clinical and Experimental Medicine, University of Padua, Padova, Italy
    Hepatology 29:1690-7. 1999
    ..Five of them were treated with the oral administration of midodrine and the parenteral administration of octreotide. In addition, the patients received 50 to 100 mL of 20% human albumin solution daily for 20 days...
  77. ncbi Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience
    Roelf Valkema
    Department of Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
    Semin Nucl Med 32:110-22. 2002
    ..receptor-positive tumors were treated with multiple doses of [(111)In-diethylenetriamine pentaacetic acid(0)]octreotide. Forty patients were evaluable after cumulative doses of at least 20 GBq up to 160 GBq...
  78. ncbi Targeted radionuclide therapy with 90Y-DOTATOC in patients with neuroendocrine tumors
    Flavio Forrer
    Institute of Nuclear Medicine, University Hospital Basel, Switzerland
    Anticancer Res 26:703-7. 2006
    The aim of this study was to assess the efficacy and safety of targeted radionuclide therapy with [90Y-DOTA0, Tyr3]-octreotide (90Y-DOTATOC) in patients with metastatic neuroendocrine tumors.
  79. ncbi Impact of somatostatin analogs on the heart in acromegaly: a metaanalysis
    Patrick Maison
    Service de Pharmacologie Clinique, Unite de recherche clinique, Assistance Publique Hopitaux de Paris, Hopital Henri Mondor, University of Paris 12, F 94010 Creteil, France
    J Clin Endocrinol Metab 92:1743-7. 2007
    ..Treatment with somatostatin analogs has been shown to improve some cardiac parameters, but most published clinical trials involved few patients and were not randomized or controlled. In addition, their results are rather variable...
  80. ncbi Rapid pituitary tumor shrinkage with dissociation between antiproliferative and antisecretory effects of a long-acting octreotide in an acromegalic patient
    Eugenia Resmini
    Department of Endocrinology and Metabolism, University of Genova, Viale Benedetto XV 6, 16132 Genoa, Italy
    J Clin Endocrinol Metab 92:1592-9. 2007
    ..However, the mechanisms of action of SSAs in inhibiting tumor growth and hormonal secretion are only partially understood, and the two effects may occur independently...
  81. ncbi Improvement of pharmacokinetics of radioiodinated Tyr(3)-octreotide by conjugation with carbohydrates
    Margret Schottelius
    Nuklearmedizinische Klinik und Poliklinik, Klinikum rechts der Isar, Technische Universitat Munchen, 81675 Munchen, Germany
    Bioconjug Chem 13:1021-30. 2002
    ..To overcome the unfavorable pharmacokinetics of radiohalogenated octreotide analogues, we evaluated three carbohydrated conjugates of Tyr(3)-octreotide (TOC)...
  82. ncbi The palliative role of 131I-MIBG and 111In-octreotide therapy in patients with metastatic progressive neuroendocrine neoplasms
    Janice L Pasieka
    Division of General Surgery, Department of Surgery, North Tower, University of Calgary and Tom Baker Cancer Center, 1403 29th Street NW, Calgary, Alberta, Canada T2N 2T9
    Surgery 136:1218-26. 2004
    Radiolabeled octreotide and metaiodobenzylguanidine (MIBG) have demonstrated limited antitumor effect on neuroendocrine neoplasms (NENs). The purpose of this study was to assess the palliative benefit of radionuclide therapy (RNT) in NENs.
  83. ncbi Three-year recurrence-free survival in a patient with recurrent medulloblastoma after resection, high-dose chemotherapy, and intrathecal Yttrium-90-labeled DOTA0-D-Phe1-Tyr3-octreotide radiopeptide brachytherapy
    Daniel Beutler
    Department of Oncology Hematology, University Children s Hospital Basel, Basel, Switzerland
    Cancer 103:869-73. 2005
    Most medulloblastomas express high levels of somatostatin type 2 receptors (sst2). DOTA0-D-Phe1-Tyr3-octreotide (DOTATOC) specifically binds sst2 in the low nanomolar range...
  84. ncbi Individualized dosimetry in patients undergoing therapy with (177)Lu-DOTA-D-Phe (1)-Tyr (3)-octreotate
    Mattias Sandström
    Department of Oncology, Radiology and Clinical Immunology, Uppsala University Hospital, 751 85, Uppsala, Sweden
    Eur J Nucl Med Mol Imaging 37:212-25. 2010
    ..The aim of this study was to investigate the feasibility and reliability of individualized dosimetry based on SPECT in comparison to conventional planar imaging...
  85. ncbi Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Via S Pansini 5, 80131 Naples, Italy
    J Clin Endocrinol Metab 91:85-92. 2006
    ..Surgery is a cornerstone in the treatment of acromegaly, but its efficacy in large, invasive tumors is scant...
  86. ncbi Micelles derivatized with octreotide as potential target-selective contrast agents in MRI
    Anna Morisco
    Department of Biological Sciences, CIRPEB, University of Naples Federico II and IBB CNR, Via Mezzocannone 16, 80134 Naples, Italy
    J Pept Sci 15:242-50. 2009
    ..three different functions: (i) the chelating agent (DTPAGlu or DOTA) able to coordinate gadolinium ion, (ii) the octreotide bioactive peptide able to target somatostatin receptors, and (iii) a hydrophobic moiety with two 18-carbon atoms ..
  87. ncbi Differential molecular mechanism of docetaxel-octreotide combined treatment according to the docetaxel-resistance status in PC3 prostate cancer cells
    Laura Lattanzio
    Laboratory of Cancer Genetics and Translational Oncology, Oncology Department, S Croce General Hospital, Cuneo, Italy
    Anticancer Drugs 24:120-30. 2013
    To examine the effect and the molecular mechanisms of the combined treatment of the somatostatin (SST) analogue octreotide with docetaxel: analysis of proliferation, apoptosis and migration in the human prostate cancer cell line PC3, ..
  88. ncbi Does the pretherapeutic tumor SUV in 68Ga DOTATOC PET predict the absorbed dose of 177Lu octreotate?
    Samer Ezziddin
    Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany
    Clin Nucl Med 37:e141-7. 2012
    ..However, no studies have yet compared standardized uptake values (SUVs) and absorbed doses in this field...
  89. ncbi Patient-specific radiation dosimetry of 99mTc-HYNIC-Tyr3-octreotide in neuroendocrine tumors
    Joshua Grimes
    Department of Physics and Astronomy, University of British Columbia, Vancouver, British Columbia, Canada
    J Nucl Med 52:1474-81. 2011
    99m)Tc-hydrazinonicotinamide-Tyr(3)-octreotide ((99m)Tc-HYNIC-TOC) is increasingly gaining acceptance as a new radiopharmaceutical for the diagnosis of pathologic lesions overexpressing somatostatin receptors...
  90. pmc Octreotide acetate in prevention of chemoradiation-induced diarrhea in anorectal cancer: randomized RTOG trial 0315
    Babu Zachariah
    Moffitt Cancer Center, Tampa, FL 33612, USA
    J Natl Cancer Inst 102:547-56. 2010
    ..Based on previous trials, octreotide acetate is widely recommended for the control of chemotherapy-induced diarrhea...
  91. ncbi Spatiotemporally controlled co-delivery of anti-vasculature agent and cytotoxic drug by octreotide-modified stealth liposomes
    Wenbing Dai
    State Key Laboratory of Natural and Biomimetic Drugs School of Pharmaceutical Sciences, Peking University, Beijing, 100191, People s Republic of China
    Pharm Res 29:2902-11. 2012
    ..Both combretastatin A-4 (CA-4) and doxorubicin (DOX) was loaded in different form in a targeted nanomedicine in order to achieve the active delivery of these two drugs followed by sequentially suppressing tumor vasculature and tumor cells...
  92. ncbi Value of combined 6-[18F]fluorodihydroxyphenylalanine PET/CT for imaging of neuroendocrine tumours
    M Schiesser
    Department of Surgery, University Hospital Zurich, Zurich, Switzerland
    Br J Surg 97:691-7. 2010
    ..This study assessed prospectively the diagnostic value and impact of combined 6-[18F]fluorodihydroxyphenylalanine positron emission tomography-computed tomography (18F-DOPA-PET/CT) in the management of NET...
  93. ncbi Neuroendocrine tumor liver metastases: use of dynamic contrast-enhanced MR imaging to monitor and predict radiolabeled octreotide therapy response
    Keiko Miyazaki
    Institute of Cancer Research, Cancer Research UK and EPSRC Cancer Imaging Centre, Sutton, Surrey SM2 5NG, England
    Radiology 263:139-48. 2012
    ..evaluate dynamic contrast-enhanced (DCE) magnetic resonance (MR) imaging for monitoring and assessing treatment response in patients with neuroendocrine liver metastases treated using yttrium 90 ((90)Y)-labeled octreotide ((90)Y-DOTATOC).
  94. pmc (111)In-octreotide scintigraphy for identification of metastatic medullary thyroid carcinoma in children and adolescents
    Maya Lodish
    Section on Endocrinology and Genetics, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Clin Endocrinol Metab 97:E207-12. 2012
    Most medullary thyroid cancers (MTC) express somatostatin receptors; therefore, (111)In-octreotide somatostatin receptor scintigraphy (SRS) may be useful in detecting sites of metastases in children with MTC.
  95. ncbi Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: the IEO phase I-II study
    Lisa Bodei
    Division of Nuclear Medicine, European Institute of Oncology, Via Ripamonti, 435 20141 Milan, Italy
    Eur J Nucl Med Mol Imaging 38:2125-35. 2011
    ..The aim of this prospective phase I-II study was to evaluate the toxicity and efficacy of (177)Lu-DOTATATE in multiple cycles...
  96. ncbi Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14
    Kathleen I Pritchard
    Sunnybrook Odette Cancer Centre and University of Toronto, Toronto, Ontario, Canada
    J Clin Oncol 29:3869-76. 2011
    ..This trial was undertaken to assess whether octreotide would lower insulin and IGF-1 levels and reduce risk of breast cancer recurrence.
  97. pmc Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours
    O Nilsson
    Department of Pathology, Sahlgrenska University Hospital, University of Gothenburg, , Sweden
    Br J Cancer 77:632-7. 1998
    ..Somatostatin receptor scintigraphy using [111In]DTPA-D-Phe1-octreotide visualized tumours in all patients (12 out of 12)...
  98. ncbi In vivo and in vitro response to octreotide LAR in a TSH-secreting adenoma: characterization of somatostatin receptor expression and role of subtype 5
    Federico Gatto
    Department of Endocrine and Medical Sciences DiSEM and Center of Excellence for Biomedical Research, University of Genova, Viale Benedetto XV, 6, 16132 Genova, Italy
    Pituitary 14:141-7. 2011
    ..We report the case of TSHoma in a 41-year-old man treated with octreotide LAR that caused a dramatic decrease of TSH and thyroid hormones and tumor shrinkage already after 3 months of ..
  99. ncbi Design, synthesis and biological activity of cell-penetrating peptide-modified octreotide analogs
    Wenlin Xie
    School of Chemistry and Chemical Engineering, Hunan University of Science and Technology, Xiangtan 411201, China
    J Pept Sci 16:105-9. 2010
    Four novel octreotide analogs with cell-penetrating peptides (CPPs) at the N-terminus or C-terminus were synthesized by a stepwise Fmoc solid-phase synthesis strategy...
  100. ncbi Impact of Multiphase 68Ga-DOTATOC-PET/CT on therapy management in patients with neuroendocrine tumors
    Juri Ruf
    Klinik fur Radiologie und Nuklearmedizin, Universitätsklinikum Magdeburg AöR, Magdeburg, Germany juri ruf med ovgu de
    Neuroendocrinology 91:101-9. 2010
    ..evaluation of the impact of integrated positron emission tomography/computed tomography (PET/CT) using (68)Ga-DOTA(0)-Phe(1)-Tyr(3)-octreotide ((68)Ga-DOTATOC) on the therapeutic management of patients with neuroendocrine tumors (NET).
  101. ncbi Control of irinotecan-induced diarrhea by octreotide after loperamide failure
    V Barbounis
    2nd Department of Medical Oncology, St Saves Hospital, Athens, Greece
    Support Care Cancer 9:258-60. 2001
    ..b>Octreotide is active against chemotherapy-induced diarrhea caused by fluoropyrimidines and irinotecan, with a distinct ..

Research Grants63

  1. The Pathobiology of Hepatic Epithelia
    Nicholas F Larusso; Fiscal Year: 2013
    ..miR-15a with accompanying decrease of Cdc25A inhibits cell proliferation and cyst growth in vitro;in PCK rats, octreotide reduces cholangiocyte cAMP and inhibits hepatic cystogenesis...
  2. Motivational Changes for Nutritionally Relevant Tastes after Gastric Bypass
    Alan C Spector; Fiscal Year: 2013
    ..Systemic administration of the somatostatin analog, octreotide, which blocks the release of these and other gut hormones, doubles short-term chow intake in rats after RYGB, ..
  3. RECEPTOR-TARGETED COPPER RADIOPHARMACEUTICALS FOR CANCER IMAGING AND THERAPY
    Carolyn J Anderson; Fiscal Year: 2012
    ..7 h;+ (17.8%);- (38.4%)). One key finding has been that 64Cu from 64Cu-TETA-octreotide was delivered to tumor cell nuclei, whereas 111In from 111In-DTPA-octreotide was found primarily in lysosomes ..
  4. Polyacridine Peptide Mediated Gene Targeting
    Kevin G Rice; Fiscal Year: 2013
    ..long-circulating multi-component PEGylated PolyAcridine Polyplexes (PPAPs) containing a fusogenic peptide and octreotide as a high affinity ligand to target cells expressing the somatostatin subtype-2 receptor (SS2)...
  5. Epigenetic Actions of Growth Hormone
    Dennis J Chia; Fiscal Year: 2012
    ..The long-acting somatostatin analog, octreotide, will be utilized to suppress endogenous GH secretion...
  6. Dosimetry Guided Phase II of 90Y-DOTA-tyr3-Octreotide + Retinoic Acid in Kids
    M SUE SUE O apos DORISIO; Fiscal Year: 2010
    ..a Phase I dose/toxicity trial for children and young adults with recurrent solid tumors using 90Y-DOTA-tyr3-Octreotide (90Y-DOTATOC) to target the somatostatin receptor type 2 (sst2) expressed on tumor cells...
  7. Targeted Therapy of Neuroendocrine Cancers Via the Notch Signaling Pathway
    Shaoqin Gong; Fiscal Year: 2013
    ..In Aim #3, a unique octreotide (OCT)-conjugated unimolecular micelle will be developed as a nanocarrier for hydrophobic Notch 1 activating ..
  8. DOSIMETRY IN CHILDREN AND YOUNG ADULTS WITH NEUROBLASTOMA OR NEUROENDOCRINE TUMOR
    M SUE O DORISIO; Fiscal Year: 2009
    ..Similarly, molecularly targeted therapy with 90Y-DOTA-tyr3-Octreotide has improved quality of life in patients with neuroendocrine tumors, but the dose is limited by toxicity to ..
  9. EXCITOTOXIN EFFECTS ON SPINAL CORD IN VITRO
    JOHN DELFS; Fiscal Year: 1992
    ..The long-term objective of this research is to understand better the role of excitotoxins in spinal neuron degeneration and death...
  10. EXERCISE AS A MEANS OF ENHANCING IMMUNITY IN THE AGED
    Jeffrey Woods; Fiscal Year: 2001
    ..we will address this by treating aged mice with bromocriptine (a dopamine agonist that suppresses PRL), and octreotide (somatostatin analog that inhibits GH)...
  11. Astatine 211 & Radioiodine Labeled Octreotide Conjugates
    Michael Zalutsky; Fiscal Year: 2004
    ..Ii this proposal, we shall focus on the development of radiohalogenated octreotide conjugates and related peptides as radiodiagnostics and therapeutics for medulloblastoma...
  12. PET imaging of carcinoid tumors to guide individualized chemotherapy
    Umar Mahmood; Fiscal Year: 2013
    ..Somatostatin analogs, including octreotide LAR, have previously been used only for symptom relief in patients with functionally active carcinoid tumors, ..
  13. DIAGNOSIS AND MANAGEMENT OF GUT/NEUROENDOCRINE TUMORS
    Aaron Vinik; Fiscal Year: 1993
    ..If it transpires that these vasoactive compounds are implicated in the symptom complex, then therapeutic modalities directed towards molecular modification of the neurokinins may prove rewarding...
  14. NUTRITION AND DRUGS REDUCE PROTEIN LOSS IN SEPSIS
    ROLAND DICKERSON; Fiscal Year: 1992
    ..Four anti-catabolic agents (propranolol, phentolamine, octreotide, and pentoxifylline) with different pharmacologic actions will be studied...
  15. ROSIGLITAZONE IN POLYCYSTIC OVARY SYNDROME
    Nicholas Cataldo; Fiscal Year: 2002
    ..Subjects with PCOS wiII have insulin resistance identified by dynamic testing using the octreotide insulin suppression test, and after further evaluation of provoked insulin secretion will receive rosiglitazone ..
  16. Image Based Evaluation of Tumor Targeting and Efficacy of Gene Therapy
    Vikas Kundra; Fiscal Year: 2010
    ..of a human somatostatin receptor gene 111 chimera in tumors using the FDA approved radiopharmaceutical in octreotide. Clinically, non-invasive methods, including anatomic imaging to assess change in tumor size, are desirable to ..
  17. THYROID HORMONE REGULATION OF MOUSE SOMATOSTATIN TYPE 5
    WHITNEY WOODMANSEE; Fiscal Year: 2004
    ..The somatostatin analog, octreotide, has been used to treat a variety of neuroendocrine tumors and description of the molecular mechanisms of the ..
  18. MOLECULAR BIOLOGY OF SOMATOSTATIN RECEPTORS
    Agnes Schonbrunn; Fiscal Year: 1993
    ....
  19. A New Approach to Peptide Radiolabeling for The Imaging of Cancer by PET
    Mark Mascal; Fiscal Year: 2009
    ..3) To attach the fluoride-binding cages to receptor-specific octreotide and RGD peptides. [4) To determine the blood plasma stability of the cage-peptide conjugates...
  20. SOUTHWEST ONCOLOGY GROUP
    Craig Nichols; Fiscal Year: 2003
    ..suppression of functioning tumors of the gastrointestinal tract and other cancers by the synthetic somatostatin (Octreotide), multiple modality therapy in the treatment of tumors such as alveolar soft part sarcoma metastatic to lung, ..
  21. IMAGING COLORECTAL CANCER WITH TC 99M VIP
    Mathew Thakur; Fiscal Year: 1999
    ..3) to compare the efficacy of Tc-99m TP 3654 with recently approved TC-99m-anti-CEA scan and In-111-DTPA-(D)-Phe-Octreotide and 4) to determine receptor specificity of the agent for other human colorectal cell lines in vitro...
  22. Non-Peptide Somatostatin Agonist Analgesics
    Gideon Shapiro; Fiscal Year: 2004
    ..on nociceptors in the skin and that activation of these receptors with a moderately selective SST2 agonist Octreotide attenuates bradykinin-induced sensitization of the nociceptors and intraplantar injection of Octreotide ..
  23. Rational Design of High-Affinity Peptide Drug Candidates
    Sriram Shankar; Fiscal Year: 2009
    ..Several short peptides have demonstrated significant ability to modulate protein-protein interactions - e.g. octreotide (SSTR2) and RGD peptides (1v23 integrins), and several others have led to the development of highly potent ..
  24. Imaging of O6-Alkylguanine-DNA Alkyltransferase
    Ganesan Vaidyanathan; Fiscal Year: 2005
    ..In summary, this proposal seeks to determine whether the development of a suitable agent for the imaging of tumor AGT will facilitate chemotherapy planning, thereby improving the outcome of alkylator chemotherapy. ..
  25. MIBG ANALOGUE RADIOPHARMACEUTICALS
    Ganesan Vaidyanathan; Fiscal Year: 2001
    ..Strategies to augment tumor-to-normal tissue ratios will be investigated. The outcome of this study should help improve the endoradiotherapy of neuroendocrine tumors and possibly of medulloblastoma. ..
  26. Radiometal-cyclized Octreotide Derivatives for Oncology
    HEATHER HENNKENS; Fiscal Year: 2008
    ..unreadable] [unreadable]..
  27. Non-Peptide Somatostatin Agonist Analgesics
    Susan Carlton; Fiscal Year: 2007
    ..by clinical studies demonstrating analgesia following systemic administration of the SST peptide analog octreotide (OCT)...
  28. PERIPHERAL SOMATOSTATIN CONTROLS INFLAMMATORY PAIN
    Susan Carlton; Fiscal Year: 2004
    ..SST, a peptide found in primary afferents, or its long lasting agonist Octreotide, has been shown to prevent peripheral sensitization...
  29. Neuropeptide Y for Cancer-Associated Anorexia
    Aminah Jatoi; Fiscal Year: 2003
    ..These two pilot studies will allow us to lay the groundwork for such larger trials. Our ultimate goal is to help cancer patients who suffer from anorexia. ..
  30. Creatine: Is It a Body Builder for Cancer Patients?
    Aminah Jatoi; Fiscal Year: 2004
    ..obtain longitudinal toxicity and quality of life data on this same cohort of 50 patients and will make direct comparisons between treatment arms on toxicity incidence and severity and on maximal quality of life scores ..
  31. NEW APPROACHES TO EVALUATION AND TREATMENT OF ACROMEGALY
    Pamela Freda; Fiscal Year: 2003
    ..My sponsor, Dr. Wardlaw, is highly qualified and committed to providing me with the support I need to pursue my research plans and to facilitate my transition to independent investigator. ..
  32. NEW APPROACHES TO EVALUATION AND TREATMENT OF ACROMEGALY
    Pamela Freda; Fiscal Year: 2003
    ..My sponsor, Dr. Wardlaw, continues to be committed to providing me with the guidance I need to pursue my research plans and to facilitate my transition to independent investigator. ..
  33. Mechanisms and Therapeutics in Cancer Anorexia/Cachexia
    Aminah Jatoi; Fiscal Year: 2004
    ..This K23 grant application will serve as a springboard to allow her to delve into the pathophysiology of this syndrome and to develop into an independent clinical investigator. ..
  34. RADIORECEPTOR GUIDED SURGERY OF NEURAL CREST TUMORS
    M O DORISIO; Fiscal Year: 2002
    ..Patients will be recruited from our nationally recognized, multidisciplinary neuroendocrine tumor clinic to participate in this trial of image guided surgical therapy. ..
  35. Phase I Trial of 90Y Octreotide in Childhood Solid Tumor
    M O DORISIO; Fiscal Year: 2002
    ..The Specific Aims are: I. Conduct a Phase I trial to determine the maximum tolerated dose of 90Y-DOTA-tyr3-Octreotide in children with refractory neuroblastoma, medulloblastoma, and other somatostatin receptor positive tumors...
  36. Non-invasive beta-cell imaging using a Ga-68-labeled glucagone-like peptide-1 ana
    Martin Gotthardt; Fiscal Year: 2008
    ..Apart from proof-of-principle studies in healthy volunteers and diabetes type I and II patients, a dosimetric method will be established to simply and reliably quantify beta-cell mass by PET imaging. [unreadable] [unreadable]..
  37. Imaging Thymidine Uptake During Treatment for Head and Neck Cancer
    Yusuf Menda; Fiscal Year: 2008
    ..The studies proposed here will refine and characterize a non-invasive imaging test that may allow treatment responses to be determined shortly after treatment has begun. [unreadable] [unreadable] [unreadable]..
  38. RADIORECEPTOR GUIDED SURGERY OF NEURAL CREST TUMORS
    M O DORISIO; Fiscal Year: 2003
    ..Patients will be recruited from our nationally recognized, multidisciplinary neuroendocrine tumor clinic to participate in this trial of image guided surgical therapy. ..
  39. 90Y-DOTA-TYR3-OCTREOTIDE IN CHILDREN W/SOMATOSTATIN REC*
    M O DORISIO; Fiscal Year: 2005
    ..Abstract Not Provided. ..
  40. Gene Expression in Prediabetes: Potential Role of PGC-1
    MARY PATTI; Fiscal Year: 2006
    ..abstract_text> ..
  41. Academic Public Private Partnership Program
    M O DORISIO; Fiscal Year: 2004
    ..abstract_text> ..
  42. scVEGF Targeted Radiotherapy of Mammary and Colonic Cancer
    FRANCIS GERARD BLANKENBERG; Fiscal Year: 2010
    ..Successful completion of our proposal will give the needed preclinical data for pursuing scVEGF targeted radiotherapy in other models and ultimately clinical applications. ..
  43. Consequences of generalized lack of GHRH
    Roberto Salvatori; Fiscal Year: 2005
    ..By recombinase technique, we will generate KO lines with no Neor, avoiding any interference with distant or neighboring genes. In addition, results obtained in the GHRHKO1 line will be confirmed or disproved. ..
  44. PSYCHOBIOLOGY OF ESTROGEN RECEPTOR MODULATORS
    Mark Wilson; Fiscal Year: 2003
    ..These data will provide not only a better understanding of the biology of SERMs but will also help clinicians and patients evaluate of these compounds on behavioral health. ..
  45. 14th International Symposium on Regulatory Peptides
    Timothy Wang; Fiscal Year: 2002
    ..abstract_text> ..
  46. Endothelial Nitric Oxide Synthase & Portal Hypertension
    Vijay Shah; Fiscal Year: 2002
    ..abstract_text> ..
  47. Regulation of Mouse Somatostatin Receptor Subtype 5 Gene
    WHITNEY WOODMANSEE; Fiscal Year: 2004
    ..The somatostatin analog, octreotide, has been used to treat a variety of neuroendocrine tumors and description of the molecular mechanisms of the ..
  48. THE ROLE OF BHLH GENES IN GLIOGENESIS AND GLIOMA BIOLOGY
    Robert Rostomily; Fiscal Year: 2004
    ..abstract_text> ..
  49. MCI, Insulin and Cholesterol in a Community Sample
    Suzanne Craft; Fiscal Year: 2010
    ..The results of this study will provide valuable information concerning the incidence and natural history of MCI, and its relation to various risk factors that may be amenable to therapeutic intervention. ..
  50. ROLE OF RETINOIDS AND RECEPTORS IN THYROTROPE FUNCTION
    BRYAN HAUGEN; Fiscal Year: 2004
    ....
  51. Inhibition of TNF in Patients with Alcoholic Hepatitis
    Vijay Shah; Fiscal Year: 2005
    ..abstract_text> ..
  52. FUNCTION AND REGULATION OF GASTRIN
    Timothy Wang; Fiscal Year: 2008
    ..Overall, these studies will attempt to define the role of progastrin-derived peptides in stem cell regulation and in bridging genetic pathways in colorectal cancer. ..
  53. Artificial Nutrition in Terminally Ill Cancer Patients
    Sydney Dy; Fiscal Year: 2007
    ..Dy with the skills she needs to develop into an independent clinical researcher in oncology palliative care decision-making and health services research. ..
  54. Regulation of Inflammation by Somatostatin via SSTR 2
    David Elliott; Fiscal Year: 2006
    ..The results of these studies will provide rationale for novel therapeutic treatment of IBD and other inflammatory diseases. ..
  55. Image-Guided Delivery and Image-Guided Evaluation of Target and Non-Target Tissue
    Vikas Kundra; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  56. Molecular Surgeon Symposium on Pancreatic Cancer
    F Brunicardi; Fiscal Year: 2003
    ..All talks will be video-taped and presented at our "The Molecular Surgeon" website for general public access. This website has been established since first symposium in 1999. ..
  57. GLUCOSE REGULATION AND MEMORY IN ALZHEIMER'S DISEASE
    Suzanne Craft; Fiscal Year: 2004
    ....
  58. HORMONE REGULATION AND PATHOGENESIS OF PITUITARY TUMORS
    Anne Klibanski; Fiscal Year: 2008
    ..abstract_text> ..
  59. NEURAL CONTROL OF LARGE INTESTINAL MUCOSA
    Helen Cooke; Fiscal Year: 2005
    ..Understanding the regulation of 5-HT may be a key to management of functional bowel disease associated with an excess or reduced number of enterochromaffin cells. ..
  60. Creation of a mouse model of isolated GH deficiency
    Roberto Salvatori; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..